Biesma 1990.

Study characteristics
Methods	Placebo‐controlled, industry‐sponsored, single‐center trial
Participants	Adults; mixed tumors; ANC < 1 x 109/L
Interventions	GM‐CSF (not specified) 2.8 mcg/kg IV ATB: Tobramicin plus Cefuroxime
Outcomes	Overall mortality Infection‐related mortality Deep vein thrombosis
Notes	Hospital discharge criteria: afebrile for at least 48 hours Duration of grade IV neutropenia reported as days to absolute granulocyte recovery to > 0.5 x 109/L
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Description of method of sequence generation not provided
Allocation concealment (selection bias)	High risk	Description of methods to conceal allocation not provided
Blinding (performance bias and detection bias) All outcomes	Low risk	Double blinding was employed
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	We were not able to assess who were blinded based on the information provided in the article
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	We were not able to assess the outcomes for which blinding was employed based on the information provided in the article
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT analysis was not used, withdrawals are described
Other bias	High risk	Prespecified values of sample size, alpha and beta errors were not provided